GSK confirms it has completed IRA negotiations ahead of CMS deadline
GSK’s incoming CEO Luke Miels said Wednesday that Medicare negotiations for the company’s top-selling respiratory product Trelegy Ellipta have concluded “in line with expectations.” The company is one...
View ArticleThermo Fisher to buy data solutions-focused Clario for up to $9.4B
Thermo Fisher announced Wednesday that it will pay $8.9 billion in cash to acquire the data solutions company Clario. In addition to the upfront payment, Thermo has agreed to shell out $125 million in...
View ArticleBIO chief to senators: China could pass US within two years
The US is at risk of losing its global lead in biotech. That was the warning Wednesday from John Crowley, CEO of the Biotechnology Innovation Organization — better known as BIO — during a sprawling...
View ArticleRoche promises $1B to China biotech for preclinical COPD bispecific
Roche is teaming up with Jiangsu, China-based Qyuns Therapeutics for a bispecific antibody that could potentially treat asthma, COPD and other respiratory diseases. To start working with the Qyuns,...
View ArticleTubulis upsizes Series C to $401M to ‘push the boundaries of ADCs’
That was fast: Two weeks after announcing a $361 million Series C, ADC startup Tubulis says it has raised another $40 million for the round, the Munich-based startup exclusively told Endpoints News ...
View ArticleNovo Nordisk proposes to acquire Metsera in bid to disrupt Pfizer's deal
Novo Nordisk is trying to throw a wrench into Pfizer's plans to become a major player in the obesity drug market. The Danish drug giant wants to buy Metsera, submitting its proposal a month after ...
View ArticleLilly blows past revenue benchmarks, again raises full-year outlook
Eli Lilly said it reeled in $17.6 billion in third-quarter revenue, beating Wall Street's projected consensus of $16.1 billion. That's a 54% jump compared to the same period in 2024, according ...
View ArticleTakeda makes some pipeline cuts, says generic competition softened sales over...
Takeda said Thursday it has ended work on several early- and mid-stage drug candidates, adding that its sales from April to September took a hit from “generic erosion” and “unfavorable” exchange rates....
View ArticleWave Life Sciences’ obesity biomarker data raise hopes for future readouts
Wave Life Sciences’ RNA therapy for obesity posted promising biomarker data in an early-stage trial on Wednesday. The update did not include weight loss data, but Wave said it believes the drug could...
View ArticleFDA puts two Intellia CRISPR trials on hold following liver toxicity case
The FDA suspended two of Intellia Therapeutics’ clinical trials of a gene editing treatment for transthyretin amyloidosis, or ATTR, a disease in which misfolded proteins build up in the heart or nerves...
View ArticleBoehringer licenses preclinical program from Kyowa Kirin; Savara makes a...
Plus, news about AbbVie, MindMed, Oculis, Veru, Sensei Biotherapeutics and Eagle Pharmaceuticals: 🤝 Boehringer Ingelheim to pay up to €640M to license Kyowa Kirin program: The German drugmaker now has...
View ArticleGoodbye, Middleman. Hello, Littleman.
With the rising success of cash-pay options for GLP-1 drugs from Eli Lilly and Novo Nordisk, more healthcare companies have been talking to me about ...
View ArticleEvommune plans to raise about $150M in IPO for inflammatory diseases
The autoimmune disease biotech Evommune said it hopes to raise about $150 million in an IPO that's expected to begin trading in the coming week. The company said it plans to ...
View ArticleNovo Nordisk’s new CEO is chasing the deals its former leaders wouldn't
Novo Nordisk brought on Maziar Mike Doustdar as CEO to make sweeping changes at the company, which is struggling to claw back the ground it's lost to Eli Lilly in the obesity market. On Thursday ...
View ArticleTectonic shares rise on back of Phase 1 heart failure data
Tectonic Therapeutic shares rose 16% Thursday morning after the biotech shared positive early-stage data from its drug candidate in certain patients with heart failure. The company’s asset, called...
View ArticleThe showdown over Metsera: Pfizer and Novo prepare for a bidding war
Two of the biggest drug companies in the world are preparing for a multibillion-dollar showdown to buy Metsera, after Novo Nordisk’s shock announcement Thursday that it had offered $1.6 billion more...
View ArticleBristol Myers Q3 earnings: Cobenfy anxiety, PD-1xVEGF strategy and MFN
Bristol Myers Squibb didn’t reveal anything earth-shattering in its third-quarter earnings report on Thursday, but rather a handful of smaller updates on its pipeline and negotiations with the Trump...
View ArticleNational Resilience secures $825M in funding; Regeneron details US...
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. National Resilience has secured $825 million in debt financing from...
View ArticlePost-Hoc Live: Breaking down the M&A drama between Pfizer, Metsera and Novo
The obesity wars just got spicier. Today, just a month after Pfizer said it would buy Metsera, Novo Nordisk swooped in with its own bid. Metsera says Novo’s offer is “superior.” Pfizer says it’s not...
View ArticleMerck CEO touts Winrevair launch, says he’s looking for deals ‘with urgency’
Merck CEO Rob Davis said on Thursday that the company is assessing ways to bring in new assets “with urgency.” The comments signal Merck’s continued appetite for deals as the company bolsters its...
View ArticleLilly CEO expects more 'noise' as Metsera M&A fight begins
Despite boasting a $1.5 billion sales beat, Eli Lilly’s earnings were overshadowed by its top competitor Novo Nordisk's efforts to usurp Pfizer in a bidding war over clinical-stage obesity biotech...
View ArticleHHS approves 340B rebate model plans for Merck, Bristol Myers and others
HHS has approved applications from eight drugmakers to participate in the government’s pilot program testing a rebate model for certain 340B discounts. The green light from HHS’ Health Resources and...
View ArticleNovo’s Metsera offer could pose a test for Trump's FTC
Novo Nordisk’s surprise $9 billion offer for obesity drugmaker Metsera could be the first major test of how the Trump administration’s FTC grapples with complex pharmaceutical mergers. The bid looks to...
View ArticleGilead sees cell therapy sales decline in Q3
Gilead Sciences said that its cell therapy revenue dropped 11% in the third quarter, compared with a year ago, citing lower demand for its two CAR-T cell therapies, Yescarta and Tecartus. The light...
View Article